Tag: Trastuzumab deruxtecan
SABCS 2019: DESTINY-Breast01 Trial of Trastuzumab Deruxtecan Shows Positive Results in...
Detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial (NCT03248492) of trastuzumab deruxtecan (DS-8201; fam-trastuzumab deruxtecan in the US only) were presented...
Advanced Design of ADCs: Principles and Applications using Next Generation Linkers...
Over the years there have been major challenges in the development of antibody-drug conjugates (ADC), including: choosing the right target, right antibody, right linker,...
Highlights in Development: September 2019
In September 2019, a number of articles discussing antibody-drug conjugates were published in a variety of journals. Here is an overview of some of...
Encouraging Preliminary Results in Treatment of Colorectal Cancer with Trastuzumab Deruxtecan
Updated Phase I safety and efficacy data for [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody-drug conjugate or ADC, were presented at the 2018 annual congress of the European Society for Medical Oncology - ESMO 2018, in Munich, Germany for a subgroup of patients with heavily pretreated HER2 expressing colorectal cancer.
Updated Results for [Fam-] Trastuzumab Deruxtecan in Patients with HER2 Mutated...
Updated phase I safety and efficacy data for trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC) being developed by Daiichi...
New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors Warrants Further...
In clinical trials, trastuzumab deruxtecan or DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated preliminary antitumor activity in...
